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Background.  —  Cardiac  amyloidosis  due  to  familial  amyloid  polyneuropathy  (FAP)  includes
restrictive cardiomyopathy,  thickened  cardiac  walls,  conduction  disorders  and  cardiac  dener-
vation. Impaired  blood  pressure  variability  has  been  documented  in  FAP  related  to  the  Val30Met
mutation.
Abbreviations: BP, blood pressure; BVP, blood pressure variability; Coeff, coefﬁcient ± standard error; cVar, coefﬁcient of variation;
DBP, diastolic blood pressure; FAP, familial amyloid polyneuropathy; LV, left ventricular; LVEF, left ventricular ejection fraction; MBP,
mean blood pressure; MIBG, metaiodobenzylguanidine; PND, polyneuropathy disability; RWT, relative wall thickness; SBP, systolic blood
pressure; SD, standard deviation; TTR, transthyretin.
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Restrictive
cardiomyopathy
Aims.  —  To  document  blood  pressure  variability  in  FAP  patients  with  various  mutation  types  and
its relationship  to  the  severity  of  cardiac  involvement.
Methods.  —  Blood  pressure  variability  was  analysed  in  49  consecutive  FAP  patients  and  was  com-
pared with  a  matched  control  population.  Cardiac  evaluation  included  echocardiography,  right
heart catheterization,  electrophysiological  study,  Holter  electrocardiogram  and  metaiodoben-
zylguanidine  (MIBG)  scintigraphy.
Results.  —  A  non-dipping  pattern  was  found  in  80%  of  FAP  patients  and  in  35%  of  control  patients
(P <  0.0001);  this  was  due  to  a  signiﬁcantly  lower  diurnal  blood  pressure  in  FAP  patients  (FAP
group, 113  ±  21  mmHg;  control  group,  124  ±  8  mmHg;  P  <  0.0001),  whereas  nocturnal  blood  pres-
sures were  similar.  Among  FAP  patients,  a  non-dipping  pattern  was  signiﬁcantly  associated  with
haemodynamic  involvement,  cardiac  thickening  or  conduction  disorders.  These  associations  did
not depend  on  the  average  blood  pressure  levels.  Impaired  blood  pressure  variability  was  more
frequent  and  more  pronounced  in  patients  with  multiple  criteria  for  severe  cardiac  amyloidosis.
Conclusion.  —  Low  blood  pressure  variability  is  common  in  cardiac  amyloidosis  due  to  FAP.  A  non-
dipping pattern  was  more  frequently  observed  in  FAP  patients  with  haemodynamic  impairment,
cardiac thickening  or  conduction  disorders.  It  is  suggested  that  impairment  of  circadian  rhythm
of blood  pressure  reﬂects  the  severity  of  cardiac  amyloidosis  due  to  FAP.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — L’amylose  cardiaque  due  à  la  polyneuropathie  familiale  amyloïde  (FAP)  est  carac-
térisée par  une  cardiopathie  restrictive,  des  troubles  conductifs  et  une  dénervation  cardiaque.
L’altération  de  la  variabilité  de  la  pression  artérielle  (VPA)  a  été  observée  chez  les  patients
présentant  une  FAP  secondaire  à  la  mutation  Val30Met.
Objectifs.  — Nous  avons  testé  l’hypothèse  qu’une  variabilité  tensionnelle  basse  serait  associée
à la  sévérité  de  l’atteinte  amyloïde  cardiaque  dans  la  FAP.
Méthodes.  — La  VPA  a  été  analysée  chez  49  patients  consécutifs  atteints  de  FAP  et  comparée
à un  groupe  témoin.  L’atteinte  cardiaque  a  été  évaluée  par  échocardiographie,  cathétérisme
droit, étude  électrophysiologique  Holter-ECG  et  scintigraphie  cardiaque  à  la  MIBG.
Résultats.  — La  VPA  était  altérée  chez  80  %  des  patients  FAP  contre  35  %  dans  le  groupe
témoin (p  <  0,0001)  et  était  due  à  une  pression  artérielle  diurne  plus  basse  dans  la  FAP
(FAP 113  ±  21  mmHg  ;  témoin  124  ±  8  mmHg  ;  p  <  0,0001),  alors  que  les  pressions  nocturnes
étaient équivalentes.  Dans  le  groupe  FAP,  le  proﬁl  « non-dipper  » était  associé  à  une  atteinte
hémodynamique,  un  épaississement  myocardique,  ou  des  troubles  conductifs  sans  différence
signiﬁcative  concernant  la  dénervation  cardiaque.  L’altération  de  la  VPA  était  plus  fréquente  et
plus prononcée  chez  les  patients  présentant  plusieurs  critères  d’atteinte  cardiaque  amyloïde.
Conclusion.  —  La  FAP  est  associée  à  une  faible  VPA.  Les  patients  présentant  une  atteinte
hémodynamique,  un  épaississement  myocardique  ou  des  troubles  conductifs  présentent  plus
fréquemment  une  VPA  altérée.  Il  semble  que  l’altération  de  la  VPA  reﬂète  la  sévérité  de
l’amylose  cardiaque  dans  la  FAP.
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ackground
lood  pressure  (BP)  is  characterized  by  a  circadian  pattern,
ith  higher  pressure  during  the  diurnal  period  than  dur-
ng  the  nocturnal  period  [1].  This  circadian  BP  variability
BPV)  is  related  to  the  imbalance  between  cardiac  output
nd  systemic  resistance  [2]  and  is  inﬂuenced  by  the  auto-
omic  nervous  system  [3,4]. A  non-dipping  proﬁle  is  deﬁned
y  a  blunted  fall  in  BP  (less  than  10%)  during  the  nocturnal
eriod  and  has  been  observed  in  various  clinical  conditions,
ncluding  systemic  hypertension,  diabetes  and  renal  failure
5—9]. The  non-dipping  proﬁle  is  also  associated  with  poor
rognosis  in  hypertensive  or  diabetic  patients  but  also  in
he  general  population  [9—11]. In  systemic  hypertension,
on-dipper  patients  display  a  worse  haemodynamic  pro-
le,  a  higher  left  ventricular  (LV)  mass  index  and  greater
s
n
i
es  droits  réservés.
eripheral  organ  damage  compared  with  dipper  patients
9,12].
Familial  amyloid  polyneuropathy  (FAP)  is  an  autonomic
ominant  disease  induced  by  the  misfolding  of  a  mutated
rotein,  transthyretin  (TTR)  [13,14]. More  than  100  differ-
nt  TTR  mutations  are  currently  described,  with  various
linical  presentations  [15]. In  Europe,  several  geographical
oci  are  reported  (Portugal,  Sweden)  and  the  most  common
utation  is  the  Val30Met  mutation  [16]. Polyneuropathy  due
o  FAP  includes  autonomic  nervous  system  impairment  and
ardiac  denervation  [17,18].  This  cardiac  autonomic  den-
rvation  is  associated  with  lower  circadian  BPV  at  the  early
tages  of  FAP  [19]. However,  cardiopathy  due  to  FAP  includes
ot  only  cardiac  denervation,  but  also  conduction  disorders,
ncreased  wall  thickness  and,  later  in  the  course  of  the  dis-
ase,  haemodynamic  impairment  with  restrictive  pattern
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[20—22]. The  precise  relationship  between  these  various
components  of  cardiac  involvement  and  BPV  is  still  unknown.
The  aim  of  our  study  was  to  document  BPV  in  FAP  patients
with  various  mutation  types.  We  tested  the  hypothesis  that
low  BPV  reﬂects  the  severity  of  cardiac  disease  in  FAP,
namely  haemodynamic  impairment,  wall  thickening  due  to
amyloid  inﬁltration,  conduction  disorders  and  cardiac  den-
ervation.
Methods
Our  retrospective,  single-centre  study  included  consecu-
tive  FAP  patients  hospitalized  from  September  2009  to  April
2011.  Patients  were  recruited  through  the  French  Reference
Centre  for  Familial  Amyloid  Polyneuropathy  and  other  Rare
Peripheral  Neuropathies.  One  patient  with  arterial  hyper-
tension  was  excluded  from  the  study  and  49  FAP  patients
entered  the  ﬁnal  analysis.  All  patients  had  high  quality
ambulatory  BP  monitoring,  which  is  part  of  our  routine
protocol  in  FAP.  The  FAP  diagnosis  was  conﬁrmed  by  TTR
genotyping.  Eleven  different  TTR  mutations  were  docu-
mented  and  the  TTR  mutation  type  was  Val30Met  in  28  over
49  patients  (57%).  Ambulatory  BP  data  were  also  obtained  in
49  age-  and  sex-matched  control  subjects.  Control  subjects
were  patients  who  were  referred  for  suspicion  of  arterial
hypertension  but  in  whom  this  diagnosis  was  ruled  out;  the
subjects  were  also  free  from  antihypertensive  treatment.
The  study  complied  with  the  Declaration  of  Helsinki  and
informed  consent  was  obtained  from  all  patients.
Clinical  status  was  evaluated  by  the  polyneuropathy  dis-
ability  (PND)  score  as  previously  described  [23]. Brieﬂy,  a
PND  score  I indicates  preserved  walking  ability;  II  indicates
that  walking  is  impaired  but  that  the  patient  is  able  to  walk
without  a  stick  or  crutch;  III  means  that  the  patient  walks
with  the  help  of  one  (or  two)  stick(s)  or  crutch(es);  and  IV
means  that  patient  is  unable  to  walk  even  with  help.
Ambulatory  BP  monitoring  was  performed  in  all  FAP
patients  according  to  the  European  Society  of  Cardiology
guidelines  [24]. The  BP  monitor  (Spacelabs  Healthcare,
Issaquah,  WA,  USA)  was  set  to  obtain  BP  readings  at  30-
minute  intervals  during  the  day  and  60-minute  intervals
during  the  night.  The  following  data  were  collected  for
each  patient:  heart  rate,  systolic  BP  (SBP),  diastolic  BP
(DBP),  mean  BP  (MBP)  and  pulse  pressure.  The  dipping  of
SBP,  DBP  and  MBP  during  the  nocturnal  period  compared
with  the  diurnal  period  was  calculated  as  follows:  dipping
(%)  =  (diurnal  BP  −  nocturnal  BP)/diurnal  BP  ×  100.  A  non-
dipper  pattern  was  diagnosed  if  the  nocturnal  decrease  in
SBP  was  inferior  to  10%  compared  with  the  diurnal  period.
The  standard  deviation  (SD)  of  BP  was  collected  for  each
patient  and  the  coefﬁcient  of  variation  (cVar)  of  BP  was
calculated.
Echocardiography  included  M-mode,  two-dimensional,
pulsed  Doppler  and  tissue  Doppler  imaging  recordings.
M-mode  allowed  the  measurement  of  LV  dimensions.  LV  ejec-
tion  fraction  (LVEF)  was  assessed  using  Simpson’s  modiﬁed
biplane  method.  Pulsed  Doppler  was  used  to  measure  peak
early  (E)  and  late  (A)  diastolic  velocities  of  the  mitral  ﬂow.
Pulsed  tissue  Doppler  imaging  of  the  lateral  LV  wall  allowed
the  measurement  of  systolic  (S)  and  early  diastolic  (Ea)
velocities.  Right  heart  catheterization  using  a  Swan-Ganz
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atheter  allowed  the  recording  of  pressure  from  the  right
trium,  right  ventricle  and  pulmonary  artery,  and  pulmonary
apillary  wedge  pressure.  Cardiac  output  was  measured  in
riplicate  using  the  thermodilution  method.
FAP-related  haemodynamic  impairment  [25]  was  diag-
osed  if  at  least  one  of  the  following  criteria  was  observed:
VEF  less  or  equal  to  50%;  pulmonary  capillary  wedge  pres-
ure  greater  than  12  mmHg;  E/Ea  ratio  greater  than  8;  E/A
atio  greater  than  2.
Cardiac  inﬁltration  was  quantiﬁed  by  measuring  inter-
entricular  septum  thickness  and  calculating  relative  wall
hickness  (RWT);  RWT  =  (2*PWTd)/LVIDd,  where  PWTd  is  pos-
erior  wall  thickness  and  LVIDd  is  LV  internal  diameter  at
nd-diastole.  Patients  with  arterial  hypertension  had  been
xcluded  at  entry  (see  above)  and  no  patient  had  aortic
tenosis.  Cardiac  thickening  was  conﬁrmed  if:  the  interven-
ricular  septum  thickness  was  greater  than  12  mm;  the  RWT
as  greater  than  0.42.
Conduction  disorders  were  evaluated  by  surface  electro-
ardiogram  and  electrophysiological  study.  The  His  bundle
otential  was  recorded  by  a  quadripolar  lead  and  the  time
etween  the  His  bundle  potential  and  ventricular  depolar-
zation  was  measured  (HV  interval).  Conduction  disorders
ere  deﬁned  by  one  of  the  following  criteria:  PR  interval
reater  or  equal  to  200  ms;  complete  bundle  branch  block
QRS  duration  ≥  120  ms);  HV  interval  greater  than  70  ms;
atients  implanted  with  a  pacemaker.
The  autonomic  nervous  system  was  evaluated  in  a
ubgroup  of  32  over  49  patients  according  to  our  rou-
ine  protocol,  based  on:  24-hour  Holter  electrocardiogram
ith  measurement  of  SD  of  normal-to-normal  RR  intervals
abnormal  if  <  100  ms);  and  123-metaiodobenzylguanidine
123-MIBG)  cardiac  scintigraphy  (heart/mediastinum  ratio  at
 hours;  normal  value  > 1.6)  [17,26,27].
tatistical analysis
ontinuous  variables  are  presented  as  mean  ±  SD.  Categori-
al  variables  are  presented  as  frequencies  and  percentages.
nalysis  of  BPV  included  circadian  BPV  (dipping  status,  level
f  dipping),  SD  of  BP  and  cVar.  The  cVar  was  calculated  as
ollows:  (SD  ×  100)/mean.  To  comply  with  the  mathematical
ormula  for  cVar  and  the  level  of  dipping,  the  relationship
etween  these  two  variables  used  the  absolute  value  of
ipping.  Comparisons  between  normal  continuous  variables
ere  performed  using  the  Mann-Whitney  test.  Categori-
al  unpaired  variables  were  compared  using  Fisher’s  exact
est.  Correlation  between  continuous  variables  was  mea-
ured  by  Spearman’s  test.  In  order  to  assess  BP  level  as
 potential  confounding  factor,  the  relationship  between
he  dipping  level  and  the  presence/absence  of  conditions
as  analysed  by  a  multiple  logistic  regression.  Levels  of
BP  and  dipping  entered  the  analysis  as  independent  varia-
les  and  the  presence/absence  of  condition  entered  the
nalysis  as  the  dependent  variable.  Results  of  the  multiple
ogistic  regression  are  expressed  as  coefﬁcient  ±  standard
rror  (Coeff)  and  P  value.  A  value  of  P  <  0.05  was  consid-
red  statistically  signiﬁcant.  The  statistical  software  used
as  Statview  (version  5.0;  SAS  Institute,  Inc.,  Cary,  NC,
SA).
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Figure 1. Mean systolic, diastolic and mean blood pressure pro-
ﬁles in patients with familial amyloid polyneuropathy compared
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Figure 2. Relationship between the absolute value of dipping and
the coefﬁcient of variation (cVar) of systolic blood pressure (SBP)
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esults
omparison between familial amyloid
olyneuropathy  and control groups
 non-dipping  pattern  was  documented  in  39  over  49  FAP
atients  (80%)  and  in  17  over  49  controls  (35%;  P  <  0.0001)
Tables  1  and  2;  Fig.  1).  Compared  with  controls,  FAP
atients  displayed  signiﬁcantly  lower  BP  values  during  the
iurnal  period,  whereas  nocturnal  BP  values  were  similar.
ver  24  hours,  FAP  patients  also  displayed  a  lower  cVar  of
P  than  control  subjects.  If  diurnal  and  nocturnal  periods
ere  considered  separately,  no  statistically  signiﬁcant  dif-
erences  were  found  between  FAP  patients  and  controls.
n  order  to  identify  the  level  of  BP  as  a  potential  con-
ounding  factor,  the  level  of  dipping  was  correlated  to  the
verage  value  of  SBP  and  to  a  variable  independent  of
verage  BP  level  (cVar  of  SBP),  in  the  overall  population
control  +  FAP,  n  =  98)  and  in  both  subgroups.  There  was  a
eak  positive  relationship  between  SBP  and  percentage  of
ipping  in  the  overall  population  (r  =  0.2,  P  = 0.03),  thus
xplaining  4%  of  the  percentage  of  dipping  (r2 =  0.04).  This
orrelation  was  not  statistically  signiﬁcant  if  FAP  patients
r  =  0.16;  P  =  0.27)  and  controls  (r  =  −0.03;  P  =  0.8)  were
onsidered  separately.  The  absolute  level  of  dipping  was
trongly  correlated  with  the  cVar  of  SBP,  not  only  in  the
verall  population  (n  =  98,  r  =  0.69;  P  <  0.0001)  but  also  in
he  FAP  group  (n  =  49,  r  =  0.58;  P  <  0.0001)  and  the  control
roup  (r  =  0.73;  P  <  0.0001)  (Fig.  2).
lood pressure proﬁle according to  cardiac
nvolvement
xtensive  characteristics  of  FAP  patients  are  displayed  in
able  3.  The  non-dipper  proﬁle  was  found  in  31  over  40
atients  with  a  polyneuropathy  disability  (PND)  score  I,  in
our  over  ﬁve  patients  with  a  PND  score  II,  in  two  over  two
atients  with  a  PND  score  III  and  in  two  over  two  patients
ith  a  PND  score  IV.  A  non-dipping  pattern  was  documented
S
a
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omong patients with familial amyloid polyneuropathy and controls.
n  22  over  28  FAP  patients  (79%)  with  the  Val30Met  mutation
nd  in  17  over  21  FAP  patients  (81%)  with  other  mutations  (P
ot  signiﬁcant).  BP  levels  (SBP,  DBP  and  MBP)  and  variabil-
ty  (dipping  of  SBP,  DBP  and  MBP)  did  not  differ  signiﬁcantly
ccording  to  mutation  type  (Val30Met  versus  other  muta-
ions).
Haemodynamic  impairment  was  documented  in  25  over
9  patients  (51%)  —  namely,  LVEF  less  or  equal  to  50%
n  =  8),  pulmonary  capillary  wedge  pressure  greater  than
2  mmHg  (n  =  8),  E/Ea  ratio  greater  than  8  (n  =  17)  and  E/A
atio  greater  than  2  (n  =  3)  — bearing  in  mind  that  one
atient  might  have  several  criteria.  Patients  with  haemo-
ynamic  impairment  exhibited  a  non-dipping  pattern  more
requently  than  patients  without  haemodynamic  impair-
ent  (92%  vs  67%,  respectively;  P  =  0.04).  Multiple  logistic
egression  also  showed  that  haemodynamic  impairment  was
ssociated  with  the  level  of  dipping  (Coeff  =  10.77  ±  4.86;
 =  0.03)  but  not  with  the  level  of  SBP  (Coeff  =  0.02  ±  0.03;
 =  0.4).  The  percentages  of  SBP,  DBP  and  MBP  dipping  were
igher  in  patients  without  haemodynamic  impairment  than
n  patients  with  haemodynamic  impairment  (Table  4).  In  FAP
atients,  the  percentage  of  SBP  dipping  was  correlated  to
he  E/Ea  ratio  (r  =  —0.33;  P  =  0.04)  but  not  to  pulmonary
apillary  wedge  pressure  or  the  E/A  ratio.  Tissue  Doppler
maging  analysis  showed  that  the  S  wave  was  also  correlated
o  dipping  of  SBP  (r  =  0.42;  P  =  0.02).
A  thickened  cardiac  wall  was  documented  in  25  over
9  patients  (51%)  and  was  due  to  an  interventricular  sep-
um  thickness  greater  than  12  mm  (n  =  2),  an  abnormal  RWT
n  =  6)  or  both  (n  =  17).  The  percentage  of  patients  with
 non-dipper  proﬁle  did  not  differ  signiﬁcantly  between
atients  with  and  without  cardiac  inﬁltration  (88%  vs  68%,
espectively;  P  =  0.15).  Multiple  logistic  regression  showed
hat  cardiac  thickening  was  associated  with  the  level  of  dip-
ing  (Coeff  =  9.44  ±  4.7;  P  =  0.047)  but  not  with  the  level  of
BP  (Coeff  =  0.04  ±  0.03;  P  =  0.2).  The  percentages  of  SBP
nd  MBP  dipping  were  higher  in  patients  without  inﬁltration
han  in  patients  with  inﬁltration  (Table  4).  The  percentage
f  SBP  dipping  was  not  correlated  to  interventricular  septum
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Table  1  General  characteristics  and  main  variables  of  the  blood  pressure  proﬁle  in  control  and  familial  amyloid  polyneu-
ropathy  groups.
Control  (n  =  49)  FAP  (n  =  49)  P
General  characteristics
Age  (years)  55  ±  13  55  ±  12  0.9
Men  33  (67.3)  33  (67.3)  1
%  of  successful  measures 89  ±  10  93  ±  7  0.05
Ambulatory  blood  pressure  monitoring
SBP  (mmHg) 120  ±  8 114  ±  13 0.007
DBP  (mmHg) 74  ±  6 72  ±  9 0.15
MBP  (mmHg) 89  ±  6 86  ±  9 0.02
PP  (mmHg)  46  ±  7  43  ±  8  0.01
Heart  rate  (bpm)  71  ±  9  74  ±  12  0.4
Ambulatory  blood  pressure  monitoring:  diurnal  period
SBP  (mmHg) 124  ±  8 113  ±  21 < 0.0001
DBP  (mmHg) 78  ±  7 72  ±  13 0.004
MBP  (mmHg) 94  ±  7 86  ±  15 0.0003
PP  (mmHg) 47  ±  7 42  ±  10 0.003
Heart  rate  (bpm) 74  ±  9 75  ±  16 0.8
Ambulatory  blood  pressure  monitoring:  nocturnal  period
SBP  (mmHg)  110  ±  9  110  ±  20  0.8
DBP  (mmHg)  65  ±  6.3  68  ±  13  0.047
MBP  (mmHg)  81  ±  7  82  ±  15  0.3
PP  (mmHg)  45  ±  7  42  ±  9  0.048
Heart  rate  (bpm)  66  ±  10  70  ±  15  0.1
Data are mean ± standard deviation or number (%). bpm: beats per minute; DBP: diastolic blood pressure; FAP: familial amyloid
polyneuropathy; MBP: mean blood pressure; PP: pulsed pressure; SBP: systolic blood pressure.
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from  a  European  population  with  the  Val30Met  mutationthickness,  posterior  wall  thickness  or  RWT  (P  =  0.25,  0.13  and
0.08,  respectively).
Conduction  disorders  were  documented  in  21  over  49
patients  (42%).  First-degree  atrioventricular  block  was  doc-
umented  in  eight  patients,  complete  bundle  branch  block
in  three  patients  and  prolonged  HV  interval  greater  than
70  ms  in  seven  patients.  Eight  patients  had  been  previously
implanted  with  a  pacemaker.  The  non-dipper  BP  proﬁle  was
more  common  in  patients  with  conduction  disorders  than  in
patients  without  conduction  disorders  (95%  vs  68%,  respec-
tively;  P  =  0.03).  Multiple  logistic  regression  showed  that
conduction  disorders  were  not  signiﬁcantly  associated  with
the  level  of  dipping  (Coeff  =  7.97  ±  4.26;  P =  0.06)  or  with
the  level  of  SBP  (Coeff  =  0.03  ±  0.03;  P  =  0.3).  The  percent-
age  of  SBP  dipping  was  not  correlated  to  the  PR  interval,
QRS  interval  or  HV  interval  (P  =  0.24,  0.34  and  0.31,  respec-
tively).
Cardiac  denervation  was  documented  in  26  over  32
patients  (81%).  The  non-dipping  proﬁle  occurred  in  21  over
26  patients  (81%)  with  cardiac  denervation  and  in  three  over
six  patients  (50%)  without  cardiac  denervation  (p  =  0.15).
Dipping  status  and  cardiac  autonomic  status  overlapped
in  24  over  32  patients  (75%).  Multiple  logistic  regres-
sion  showed  that  cardiac  denervation  was  not  signiﬁcantly
associated  with  the  level  of  dipping  (Coeff  = 7.37  ±  1.16;
P  =  0.28)  or  with  the  level  of  SBP  (Coeff  =  0.04  ±  0.31;
P  =  0.31).  Finally,  Table  4  shows  that  the  BP  dipping  did  not
differ  signiﬁcantly  according  to  cardiac  denervation.
(
s
Fnteraction between blood pressure variability
nd cardiac amyloidosis severity
onduction  disorders,  thickened  cardiac  walls  and  func-
ional  restrictive  pattern  were  the  three  criteria  reﬂecting
he  severity  of  cardiac  involvement.  In  our  FAP  patients
n  =  49),  12  patients  had  three  criteria,  11  patients  had
wo  criteria,  13  patients  had  one  criterion  and  13  patients
isplayed  neurological  symptoms  without  any  criteria  for
evere  cardiac  amyloidosis.  A  non-dipper  proﬁle  was  doc-
mented  in  eight  over  13  patients  (62%)  with  0  criterion,
ine  over  13  patients  (69%)  with  one  criterion,  11  over  12
atients  (91%)  with  two  criteria  and  12  over  12  patients
100%)  with  three  criteria  for  cardiac  amyloidosis.  Compared
ith  controls,  SBP  dipping  was  lower  in  each  of  these  sub-
roups  of  FAP  patients  (Fig.  3).  SBP  dipping  was  lower  in
atients  with  three  criteria  than  in  patients  with  no  criteria
r  one  criterion  (5.8%  and  5.9%  vs  —3.8%;  P  =  0.03  and  0.01,
espectively).
iscussion
he  present  retrospective  study  included  49  FAP  patients57%)  and  free  from  arterial  hypertension,  and  49  age-  and
ex-matched  normotensive  controls.  BPV  was  lower  in  the
AP  group  than  in  the  control  group.  Impaired  BPV  was
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Table  2  Characteristics  of  blood  pressure  variability  in  control  and  familial  amyloid  polyneuropathy  groups.
Control  (n  =  49)  FAP  (n  =  9)  P
Blood  pressure  dipping
Non-dipper  patients  n  (%)  17  (35)  39  (80)  <  0.0001
Dipping  SBP  (%)  11  ±  6  3  ±  8  <  0.0001
Dipping  DBP  (%)  16  ±  7  5  ±  9  <  0.0001
Dipping  MBP  (%) 14 ±  7  4  ±  8  <  0.0001
Blood  pressure  variability:  diurnal  and  nocturnal  periods
SBP
SD  (mmHg) 12  ±  9 10 ±  10 0.0009
cVar  (%) 10 ±  3 9 ±  3 0.01
DBP
SD  (mmHg)  10  ±  5  8  ±  4  0.0001
cVar  (%)  14  ±  3  12  ±  3  0.0003
MBP
SD  (mmHg)  11  ±  2  9  ±  2  0.0004
cVar  (%)  12  ±  3  10  ±  3  0.003
PP
SD  (mmHg)  8  ±  3  7  ±  2  0.0004
cVar  (%)  17  ±  4  16  ±  4  0.02
Heart  rate
SD  (mmHg)  10  ±  3  7  ±  4  <  0.0001
cVar  (%)  13  ±  5  9  ±  5  <  0.0001
Blood  pressure  variability:  diurnal  period
SBP
SD  (mmHg)  11  ±  3  10  ±  3  0.03
cVar  (%)  9  ±  2  11  ±  14  0.7
DBP
SD  (mmHg)  9  ±  2  8  ±  2  0.02
cVar  (%)  11  ±  3  13  ±  12  0.5
MBP
SD  (mmHg)  10  ±  2  9  ±  2  0.02
cVar  (%)  10  ±  2  12  ±  13  0.6
PP
SD  (mmHg) 8  ±  2  7  ±  2  0.0004
cVar  (%)  17  ±  4  18  ±  13  0.2
Heart  rate
SD  (mmHg) 9  ±  3 7 ±  4  <  0.0001
cVar  (%)  13  ±  5  11  ±  13  <  0.0001
Blood  pressure  variability:  nocturnal  period
SBP
SD  (mmHg)  9  ±  4  9  ±  3  0.5
cVar  (%)  9  ±  4  9  ±  3  0.5
DBP
SD  (mmHg)  8  ±  2  8  ±  3  0.1
cVar  (%)  8  ±  2  8  ±  3  0.1
MBP
SD  (mmHg)  8  ±  3  8  ±  3  0.5
cVar  (%)  8  ±  3  8  ±  3  0.5
PP
SD  (mmHg) 6  ±  2 5 ±  2  0.045
cVar  (%) 6 ±  2 5 ±  2 0.045
Heart  rate
SD  (mmHg) 6  ±  2 4 ±  3 0.01
cVar  (%)  6  ±  2  4  ±  3  0.01
Data are mean ± standard deviation or number (%). cVar: coefﬁcient of variation; DBP: diastolic blood pressure; FAP: familial amyloid
polyneuropathy; MBP: mean blood pressure; PP: pulsed pressure; SD: standard deviation; SBP: systolic blood pressure.
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Table  3  Characteristics  of  the  familial  amyloid
polyneuropathy  group.
Variable  Value
General  characteristics
Delay  between  diagnosis  of  FAP  and
ABPM  (years)
6 ±  6
Body  mass  index  (kg/m2)  25 ±  4
Creatinine  clearance  (mL/min)a 79 ±  25
Right  catheterization
Pulmonary  capillary  wedge  pressure
(mmHg)
9 ±  4
Systolic  pulmonary  arterial  pressure
(mmHg)
27  ±  10
Diastolic  pulmonary  arterial
pressure  (mmHg)
10 ±  4
Mean  pulmonary  arterial  pressure
(mmHg)
15  ±  6
Mean  right  atrial  pressure  (mmHg)  4  ±  2
Cardiac  index  (L/min/m2)  3.0  ±  0.6
Echocardiography
Interventricular  septum  thickness
(mm)
12 ±  4
Posterior  wall  thickness  (mm)  10  ±  3
LV  end  diastolic  diameter  (mm)  46  ±  6
Left  atrial  diameter  (mm)  36  ±  8
Relative  wall  thickness  0.46  ±  0.15
LV  ejection  fraction  (%)  60  ±  10
Mitral  E/A  ratio  1.1  ±  0.5
Mitral  E/Ea  ratio  9.0  ±  4.8
TDI:  lateral  ventricular  S  wave
(cm/s)
14  ±  4
Electrophysiological  study
PR  interval  (ms) 182  ±  29
QRS  interval  (ms) 89 ± 21
AH  interval  (ms) 115 ± 76
HV  interval  (ms) 60 ± 12
Data are mean ± standard deviation. ABPM: ambulatory blood
pressure monitoring; FAP: familial amyloid polyneuropathy; LV:
left ventricular; TDI: tissue Doppler imaging.
a Calculated using the Cockcroft-Gault formula.
Figure 3. Dipping of systolic blood pressure (%) according to
the severity of cardiac amyloidosis. Cardiac amyloidosis criteria
included haemodynamic involvement, cardiac wall thickening and
conduction disorders. Values are expressed as mean and standard
error of the mean. Control group versus familial amyloid polyneu-
ropathy (FAP) group, P < 0.0001; control group versus no criteria,
P = 0.01; control group versus one criterion, P = 0.005; control group
versus two criteria, P = 0.0003; control group versus three criteria,
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idocumented  in  80%  of  FAP  patients.  Abnormal  BPV  was  asso-
ciated  with  impaired  haemodynamic  status,  cardiac  wall
thickening  and  conduction  disorders.  Impaired  BPV  was
observed  in  the  early  stages  of  FAP  and  was  more  pronounced
in  patients  with  severe  cardiac  amyloidosis.  These  results
suggested  that  impaired  BPV  was  associated  with  several
components  of  cardiac  amyloidosis  due  to  FAP  and  reﬂected
the  severity  of  cardiac  inﬁltration.
Circardian  BPV  is  related  to  the  imbalance  between  car-
diac  output  and  systemic  vascular  resistance.  During  the
nocturnal  period,  cardiac  output  decreases,  whereas  sys-
temic  vascular  resistances  do  not  change  or  are  higher  than
during  the  diurnal  period,  resulting  in  a  drop  in  BP  [2].  A  cut-
off  value  of  10%  has  been  used  since  1988  to  deﬁne  dippers
and  non-dippers  [28]. The  non-dipping  pattern  is  commonly
found  in  one  fourth  to  one  third  of  the  general  healthy
a
s
s < 0.0001; no criteria versus three criteria, P = 0.03; one criterion
ersus three criteria, P = 0.01.
opulation  and  is  associated  with  age,  sex  and  hyperten-
ive  status  [29]. The  35%  value  of  non-dippers  documented
n  our  control  group  is  thus  at  the  upper  limit  of  the  pub-
ished  values  [29]. This  may  be  explained  by  the  fact  that
e  did  not  study  healthy  volunteers  but  patients  with  sus-
icion  of  arterial  hypertension,  in  whom  this  diagnosis  was
uled  out.  In  patients  with  systemic  hypertension,  the  non-
ipping  pattern  is  due  to  a  blunted  decrease  in  BP  during  the
ight  (related  to  an  increase  in  systemic  vascular  resistance
30]  or  a  blunted  decrease  in  cardiac  output  during  the  night
31]).
The  non-dipping  pattern  has  been  constantly  associated
ith  a  worse  prognosis  in  systemic  hypertension  [10,32]  and
iabetes  [11,33],  and  also  among  the  general  population
34]. In  hypertension,  a  non-dipping  proﬁle  is  associated
ith  impaired  endothelial  function  [35]  and  a  higher  LV  mass
ndex  [12]. A  non-dipping  proﬁle  is  also  associated  with  an
ncreased  risk  of  cardiovascular  mortality  [34].
To  the  best  of  our  knowledge,  only  a  few  studies  have  doc-
mented  BPV  in  cardiac  FAP,  all  of  which  were  performed  on
AP  patients  with  the  Val30Met  mutation  by  the  same  Por-
uguese  team.  In  a  large  cohort  (n  =  212)  with  various  stages
f  autonomic  impairment,  Carvalho  et  al.  [19]  demonstrated
hat  the  dipping  level  progressively  decreases  as  dysautono-
ia  progresses.  They  also  showed  that  FAP  induces  both
arly  parasympathetic  failure  and  delayed  sympathetic  fail-
re  [5,18]. Our  results  conﬁrmed  that  variables  integrating
ircadian  variability,  such  as  the  level  of  dipping  and  the
lobal  cVar  of  BP,  are  decreased  in  FAP.  A  second  study  by  the
ame  team  demonstrated  that  secretions  of  noradrenaline
nd  adrenaline  in  response  to  orthostatic  challenge  were  low
n  FAP  due  to  the  Val30Met  mutation  and  that  this  was  associ-
ted  with  a  blunted  rise  in  total  peripheral  resistance  during
upine  stress  [36]. Moreover,  BP  overshoot  after  tilt  rever-
al  was  higher  in  FAP  patients  than  in  control  subjects  [37].
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Table  4  Comparison  of  blood  pressure  variability  according  to  cardiac  involvement  in  familial  amyloid  polyneuropathy.
Cardiac  involvement  in  FAP  P
Haemodynamic  impairment  No  haemodynamic  impairment
SBP
Mean  (mmHg) 112 ± 12  117 ±  14  0.2
Dipping  (%)a —0.4  ±  8.8  5.8  ±  6.2  0.01
DBP
Mean  (mmHg)  71  ±  8  73  ±  8  0.2
Dipping  (%)a 2.2  ±  9.4  7.6  ±  8.4  0.03
MBP
Mean  (mmHg)  85  ±  9  88  ±  10  0.2
Dipping  (%)a 1.7 ±  8.7  7.0  ±  7.3  0.02
Cardiac  thickening  No  cardiac  thickening
SBP
Mean  (mmHg)  112  ±  14  118  ±  11  0.04
Dipping  (%)a 0  ±  9  5.5  ±  6.2  0.03
DBP
Mean  (mmHg)  72  ±  9  73  ±  8  0.5
Dipping  (%)a 2.5  ±  9.7  7.3  ±  8.5  0.09
MBP
Mean  (mmHg)  85  ±  10  88  ±  8  0.2
Dipping  (%)a 1.7  ±  8.9  6.8  ±  7.2  0.046
Conduction  disorders  No  conduction  disorders
SBP
Mean  (mmHg) 112  ±  10  116  ±  15  0.3
Dipping  (%)a 0.0 ±  9.8  4.9  ±  6.0  0.14
DBP
Mean  (mmHg) 72 ±  8  71  ±  9  0.6
Dipping  (%)a 2.0 ±  10.0  7.0 ±  8.1  0.07
MBP
Mean  (mmHg) 86 ±  8  87 ±  10  0.8
Dipping  (%)a 1.6 ±  9.4  6.4 ±  7.1  0.07
Cardiac  denervation  No  cardiac  denervation
SBP
Mean  (mmHg)  115  ±  11  122  ±  19  0.5
Dipping  (%)a 2.3  ±  8.5  6.8  ±  7.5  0.2
DBP
Mean  (mmHg)  72  ±  7  78  ±  10  0.13
Dipping  (%)a 4.0  ±  9.9  8.2  ±  9.9  0.2
MBP
Mean  (mmHg) 87  ±  8  93  ±  13  0.2
Dipping  (%)a 3.8  ±  9.2  7.0  ±  7.6  0.3
Data are mean ± standard deviation. DBP: diastolic blood pressure; FAP: familial amyloid polyneuropathy; MBP: mean blood pressure;
SBP: systolic blood pressure.
a Dipping (%) = (diurnal blood pressure − nocturnal blood pressure)/diurnal blood pressure × 100.
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ihese  impaired  BP  responses  during  orthostatic  challenge  or
ilt  reversal  may  paradoxically  increase  BPV.  Conversely,  BPV
valuated  during  relative  short  periods  of  time  (diurnal  or
octurnal  cVar)  did  not  differ  signiﬁcantly  between  the  FAP
nd  control  groups.  Finally,  our  data  conﬁrmed  that  the  non-
ipping  pattern  was  due  to  a  blunted  rise  of  BP  during  the
iurnal  period  compared  with  controls,  and  not  to  a  blunted
2
w
decrease  in  BP  during  the  night.  This  potential  physiopatho-
ogical  mechanism  would  negatively  mirror  those  described
n  systemic  hypertension.In  our  study,  a  non-dipping  proﬁle  was  documented  in
2  over  28  FAP  patients  with  the  Val30Met  mutation  (79%),
hich  conﬁrms  previous  ﬁndings  [19]. Moreover,  we  also
ocumented  the  same  high  prevalence  of  the  non-dipping
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proﬁle  in  FAP  patients  with  other  types  of  mutation  (17/21,
81%).  Cardiac  denervation  was  precisely  assessed  in  a  sub-
group  of  32  patients  by  using  classic  heart  rate  variability
and  MIBG  scintigraphy  criteria.  Interestingly,  the  dipping  sta-
tus  and  the  cardiac  autonomic  status  overlapped  in  24  over
32  patients  (75%).
In  keeping  with  previous  ﬁndings  [19], our  study  also  doc-
umented  that  impaired  BPV  may  occur  early  in  the  course
of  the  disease.  Indeed,  the  non-dipping  proﬁle  was  docu-
mented  in  patients  with  few  speciﬁc  criteria  for  cardiac
involvement  (no  criteria  or  one  criterion).  However,  BPV
values  markedly  differed  among  FAP  patients  and  one  new
ﬁnding  of  our  study  was  that  cardiac  denervation  was  not
the  only  factor  associated  with  impaired  BPV.  The  amount
of  cardiac  involvement  appeared  to  play  a  signiﬁcant  role.
Indeed,  BP  dipping  was  lower  and  even  reversed  in  patients
with  three  criteria  for  cardiac  amyloidosis.  Taken  together,
these  results  suggested  that  BPV  decreased  in  a  two-step
manner  in  FAP:  a  ﬁrst  step  related  to  early  dysautonomia;
and  a  second  step  associated  with  the  severity  of  cardiac
amyloidosis.  Interestingly,  non-dipper  hypertensive  patients
display  higher  cardiac  remodelling  compared  with  dipper
patients,  as  assessed  by  echocardiography  (LV  mass,  inter-
ventricular  septum  and  left  atrial  diameter),  despite  similar
BP  values  [32].
Limitations and implications
This  was  a  single-centre,  cross-sectional  study.  Selection
bias  was  minimized  as  we  only  excluded  patients  with  sys-
temic  hypertension  from  the  analysis.  The  results  pertained
strictly  to  our  European  population  with  a  high  prevalence
of  the  Val30Met  mutation  (57%).  However,  a  large  panel  of
different  mutations  was  represented  in  our  cohort.  Finally,
the  absence  of  a  signiﬁcant  association  between  dipping  sta-
tus  and  cardiac  involvement  variables  and  the  discrepancy
between  statistical  analyses  may  reﬂect  a  lack  of  statistical
power,  thus  preventing  us  to  draw  ﬁrm  conclusions  on  these
analyzes.
It  is  suggested  that  BPV  may  be  a  promising,  non-invasive
tool  reﬂecting  the  severity  of  cardiac  amyloidosis.  Evalua-
tion  of  BPV  is  a  recognized,  non-invasive,  prognostic  tool  in
various  cardiovascular  diseases  [9].  Thus,  further  studies  are
needed  to  test  this  hypothesis  speciﬁcally  in  FAP.
Conclusion
In  our  European  population  with  the  Val30Met  mutation
(57%)  and  free  from  arterial  hypertension,  the  present  ret-
rospective  study  documented  that  80%  were  non-dipper
patients.  This  was  mainly  explained  by  a  blunted  rise  in  BP
during  the  diurnal  period.  In  FAP,  SBP  dipping  was  associated
with  impaired  haemodynamic  status,  cardiac  wall  thicken-
ing  and  conduction  disorders.  Impaired  BPV  occurred  early
in  FAP  and  was  more  pronounced  in  severe  cardiac  amyloido-
sis.  BPV  may  be  a  promising,  non-invasive  tool  reﬂecting  the
severity  of  cardiac  amyloidosis  due  to  FAP.  The  prognostic
implications  of  our  results  deserve  further  studies.
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